In this Trendline, we'll take an in depth look inside the booming weight loss drug market.
Known as GLP-1 agonists, new drugs could change how doctors treat obesity and, possibly, how the condition is more broadly understood. They could also raise healthcare spending substantially, posing a problem for insurers looking to control costs.
Included in this Trendline:
Offered Free by: BioPharma Dive and OPEN Health
See All Resources from: BioPharma Dive and OPEN Health